Charles River Laboratories International (CRL) Revenue — Quarter Ended Mar 29, 2025
Revenue declined in the current quarter compared to both the immediately preceding quarter and the same quarter one year earlier. The decrease reflects a continuation of the downward trend observed in recent periods.
Key takeaway
Quarter ended Mar 29, 2025 · FY2025 Q1
Revenue declined in the current quarter compared to both the immediately preceding quarter and the same quarter one year earlier. The decrease reflects a continuation of the downward trend observed in recent periods.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$984.2M
Revenue reported for this quarter.
Quarter-over-quarter
-1.8%
Change from the immediately preceding quarter.
Year-over-year
-2.7%
Change from the comparable year-ago quarter.
Trailing four quarters
$4B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Jun 29, 2024 | $1B | -3.2% |
| Sep 28, 2024 | $1B | -1.6% |
| Dec 28, 2024 | $1B | -1.1% |
| Mar 29, 2025 | $984.2M | -2.7% |
Revenue performance
Revenue for the quarter was lower than the prior quarter, marking a sequential decline. It also fell short of the level reported in the same quarter of the prior year.
Quarterly comparison
Compared with the immediately preceding quarter, revenue decreased. When measured against the same quarter one year earlier, revenue was also lower.
What to watch
The filing discusses risk factors including U.S. government investigations and a securities class action lawsuit related to the non-human primate supply chain.